Glooko and mylife Diabetes Care announced on 12 May 2026 that Glooko will become mylife Diabetes Care’s primary data management platform for mylife products, including mylife Loop powered by mylife CamAPS FX. The company release is mirrored on Business Wire and Glooko’s own site, with consistent terms and no material discrepancy found. (Business Wire announcement, Glooko announcement)

60-second thesis frame

This is less a product launch than a workflow-control move: mylife appears to be consolidating diabetes data sharing around Glooko while phasing out parts of its own legacy digital stack. The diligence question is whether Glooko becomes a sticky clinic-facing data layer for automated insulin delivery, or merely a replaceable connector behind pump and CGM ecosystems. Confidence rises if migration is smooth, clinician workflow burden falls, and payers or clinics see evidence that connected AID data improves follow-up quality. Confidence falls if onboarding friction, data latency, cyber/privacy scrutiny, or EHR integration limits keep usage shallow. mylife says mylife Cloud, mylife Software, mylife Uploader, and mylife Dongle will be phased out by end-December 2026, while CamAPS-to-Glooko syncing can take up to 48 hours. (mylife Cloud phase-out, Glooko CamAPS connection guide)

The seven diligence questions

Clinical

• Does moving mylife Loop data into Glooko improve actual care decisions, such as faster insulin-setting reviews, safer AID titration, and better time-in-range follow-up, or only improve data availability?

• Can Glooko preserve clinically relevant context from mylife CamAPS FX, including CGM, pump, auto-mode, alert, bolus, and target data, given that mylife describes automated upload from CamAPS FX to mylife Cloud or Glooko for healthcare-professional sharing? (mylife Loop product page)

Payer or Access

• Will payers view Glooko-enabled remote review as a reimbursable workflow, a prerequisite for AID support, or an unfunded administrative layer?

• Does consolidation on Glooko help clinics document outcomes, adherence, and device use in a way that supports CGM or pump reimbursement, especially where eligibility and local timelines differ?

Ops or Adoption

• How many mylife users and clinics need migration before end-December 2026, and what failure rate is acceptable when historical data export, account linking, and clinic invitations are required? (mylife Cloud phase-out)

Competitive

• Does Glooko’s claim to support more than 200 diabetes and health-monitoring devices create meaningful network effects versus device-native portals, CGM apps, and EHR modules? (ADCES DANA Glooko profile)

Team or Cap table

• Does the agreement signal a deeper commercial dependency between mylife and Glooko, and who controls economics, data rights, customer support obligations, and future product roadmap priorities?

Red flags

• Migration is framed as continuity, but mylife’s own phase-out page points users from legacy tools toward Glooko, so poor transition execution could create patient and clinic friction rather than platform stickiness. (mylife Cloud phase-out)

• Clinical value is not yet evidenced in this announcement. The release says the partnership supports clinical practice and outcomes, but it does not disclose usage numbers, outcome data, revenue terms, or payer commitments. (Glooko announcement)

• Glooko’s regulated history supports data-management positioning, but its FDA-cleared indication explicitly says the system is not intended to provide treatment decisions or substitute for professional healthcare advice, limiting how aggressively value can be claimed. (FDA 510(k) summary K122142)

Next catalyst

Watch for local migration notices, clinic onboarding evidence, and support metrics before the end-December 2026 phase-out of mylife Cloud, mylife Software, mylife Uploader, and mylife Dongle. (mylife Cloud phase-out)

FAQ

What exactly changed by Glooko and mylife Diabetes Care’s “Expand Diabetes Data Management Partnership” news on 12 May 2026, and why does it matter for connected diabetes care?

Glooko and mylife Diabetes Care said Glooko will serve as the primary data-management platform for mylife products, including mylife Loop powered by mylife CamAPS FX. The strategic relevance is that clinic-facing diabetes data workflows may consolidate around Glooko as mylife users and healthcare teams manage AID data. (Business Wire announcement, Glooko announcement)

What is the operational path after Glooko and mylife Diabetes Care’s 12 May 2026 partnership expansion?

mylife tells users of mylife Cloud plus mylife Loop to start sharing CamAPS FX data with Glooko and ask their healthcare provider to review it in Glooko. It also says mylife Software, mylife Uploader, and mylife Dongle will be phased out by the end of December 2026, making migration execution a near-term diligence item. (mylife Cloud phase-out)

Which product capabilities matter most after Glooko and mylife Diabetes Care’s 12 May 2026 announcement?

mylife Loop combines the mylife YpsoPump, mylife CamAPS FX app, and compatible CGM sensors, with the app adjusting insulin delivery every 8–12 minutes based on sensor readings. The data-management layer matters because mylife says automated upload from CamAPS FX to mylife Cloud or Glooko supports data sharing with healthcare professionals. (mylife Loop product page)

What safety or regulatory issues matter after Glooko and mylife Diabetes Care’s 12 May 2026 announcement?

The announcement does not present new clinical safety data or a new regulatory clearance. A key boundary is that Glooko’s FDA-cleared data-management software is intended to aid review and analysis, not to provide treatment decisions or substitute for professional healthcare advice. (FDA 510(k) summary K122142)

How could clinics and payers evaluate access after Glooko and mylife Diabetes Care’s 12 May 2026 partnership expansion?

Clinics may focus on whether Glooko reduces review burden, supports remote monitoring, and integrates with EHR workflows. ADCES describes Glooko as a diabetes data-management platform with device syncing, automatic data sharing with care teams where clinics participate, and EHR integration. (ADCES DANA Glooko profile)

Publisher / Disclosure

Publisher: LucidQuest Ventures Ltd. Produced: 13 May 2026, 07:58 London. Purpose: general and impersonal information. Not investment research or advice, no offer or solicitation, no suitability assessment. UK: directed at investment professionals under Article 19(5) and certain high-net-worth entities under Article 49(2)(a)–(d) of the Financial Promotion Order 2005. Others should not act on this. Sources and accuracy: public sources believed reliable, provided “as is,” may change without notice. No duty to update. Past performance is not reliable. Forward-looking statements carry risks. Methodology: questions-first framework using public sources. No conflicts. Authors do not hold positions unless stated. © 2026 LucidQuest Ventures Ltd.

Entities / Keywords

Glooko; mylife Diabetes Care; Ypsomed; TecMed; CamDiab; mylife Loop; mylife CamAPS FX; YpsoPump; Dexcom G6; Dexcom G7; FreeStyle Libre 3; FreeStyle Libre 3 Plus; CGM; automated insulin delivery; AID; hybrid closed loop; diabetes data management; diabetes remote monitoring; EHR integration; FDA; 510(k); K122142; ADCES; DANA; payer access; reimbursement; clinic workflow; mylife Cloud; mylife Software; mylife Uploader; mylife Dongle; end-December 2026; Europe; UK; Switzerland; Gothenburg; Burgdorf; type 1 diabetes; pregnant women with type 1 diabetes; glycemic safety; time in range.